Who owns BridgeBio Pharma (BBIO)? Superinvestor holders
8 superinvestors of the 157 tracked here hold BridgeBio Pharma (BBIO) in their latest 13F filing, with $2.7B between them. Andrew Spokes gives it the most weight: 4.89% of the reported portfolio.
Key facts
- Superinvestors holding it
- 8 of 157
- Biggest holder
- Andrew Spokes, $937.5M
- Largest weight
- Andrew Spokes, 4.89%of their portfolio
- Combined value
- $2.7B
- Bought last quarter
- 6
- Sold last quarter
- 2
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Andrew SpokesFarallon Capital Management | 4.89% | $937.5M | 14.25M | ▲ Added 33% | +3.5M | Q3 2026 |
| 2 | Andreas HalvorsenViking Global Investors | 2.11% | $741M | 9.95M | ▼ Reduced 16% | −1.89M | Q2 2026 |
| 3 | John Overdeck and David Siegel (founders)Two Sigma Investments | 0.18% | $240.8M | 3.66M | ▼ Reduced 22% | −1.06M | Q3 2026 |
| 4 | Steve CohenPoint72 Asset Management | 0.17% | $113.6M | 1.53M | New | +1.53M | Q2 2026 |
| 5 | David Shaw (founder)D. E. Shaw & Co. | 0.17% | $270.6M | 3.63M | ▲ Added 43% | +1.09M | Q2 2026 |
| 6 | Ken GriffinCitadel Advisors | 0.16% | $280M | 3.76M | ▲ Added 18% | +586.21K | Q2 2026 |
| 7 | Ray Dalio (founder)Bridgewater Associates | 0.14% | $33.4M | 448.14K | ▲ Added 73% | +188.68K | Q2 2026 |
| 8 | Primecap teamPrimecap Management | 0.07% | $111.8M | 1.7M | ▲ Added 67% | +683.45K | Q3 2026 |
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 3 | 19.61M | $1.3B | 2 | 1 |
| Q2 2026 | 157 | 7 | 34.78M | $2.6B | 6 | 1 |
| Q1 2026 | 157 | 5 | 27.55M | $2B | 4 | 1 |
| Q4 2025 | 157 | 4 | 25.38M | $1.9B | 2 | 2 |
| Q3 2025 | 157 | 4 | 26.53M | $1.4B | 2 | 2 |
| Q2 2025 | 157 | 3 | 26.49M | $1.1B | 2 | 2 |
| Q1 2025 | 156 | 3 | 28.22M | $975.7M | 2 | 2 |
| Q4 2024 | 156 | 3 | 30.34M | $832.5M | 1 | 0 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Andrew Spokes | 14.25M | 10.74M | 9.37M | 9M | 8.19M | 7.9M | 5.73M | 4.2M |
| John Overdeck and David Siegel (founders) | 3.66M | 4.72M | 3.12M | 1.95M | 2.33M | — | — | — |
| Primecap team | 1.7M | — | — | — | — | — | — | — |
| Andreas Halvorsen | · | 9.95M | 11.84M | 14.39M | 15.98M | 18.56M | 22.06M | 25.12M |
| Ken Griffin | · | 3.76M | 3.17M | — | — | — | — | — |
| David Shaw (founder) | · | 3.63M | — | — | — | — | — | — |
| Steve Cohen | · | 1.53M | — | — | — | — | — | — |
| Ray Dalio (founder) | · | 448.14K | — | — | — | — | — | — |
| Polen Capital team | — | — | 45.93K | 38.24K | 36.16K | 35.65K | — | — |
| Stanley Druckenmiller | · | — | — | — | — | — | 438.05K | — |
| Zhang Lei | · | — | — | — | — | — | — | 1.02M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own BBIO?
In their latest 13F filings: Andrew Spokes (4.89% of the portfolio, $937.5M), Andreas Halvorsen (2.11% of the portfolio, $741M), John Overdeck and David Siegel (founders) (0.18% of the portfolio, $240.8M), Steve Cohen (0.17% of the portfolio, $113.6M), David Shaw (founder) (0.17% of the portfolio, $270.6M), Ken Griffin (0.16% of the portfolio, $280M), Ray Dalio (founder) (0.14% of the portfolio, $33.4M), Primecap team (0.07% of the portfolio, $111.8M).
Who bought BBIO last quarter?
Andrew Spokes (added 33%), Steve Cohen (new position), David Shaw (founder) (added 43%), Ken Griffin (added 18%), Ray Dalio (founder) (added 73%), Primecap team (added 67%). “Last quarter” is each investor's latest reported quarter.
Who sold BBIO last quarter?
Reduced: Andreas Halvorsen (16% fewer shares), John Overdeck and David Siegel (founders) (22% fewer shares).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns BridgeBio Pharma (BBIO)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/BBIO/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to BBIO by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.